BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol 2018;183:538-56. [DOI: 10.1111/bjh.15684] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Swan D, Thachil J. Management of haemostatic complications of chimaeric antigen receptor T-cell therapy. Br J Haematol 2022. [PMID: 35146749 DOI: 10.1111/bjh.18045] [Reference Citation Analysis]
2 Martinez-Sanchez J, Palomo M, Torramade-Moix S, Moreno-Castaño AB, Rovira M, Gutiérrez-García G, Fernández-Avilés F, Escolar G, Penack O, Rosiñol L, Carreras E, Diaz-Ricart M. The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Bone Marrow Transplant 2020;55:2270-8. [PMID: 32404979 DOI: 10.1038/s41409-020-0947-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sorigue M, Cañamero E, Siguenza P, Nomdedeu M, López-núñez JJ. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leukemia & Lymphoma 2020;61:1277-91. [DOI: 10.1080/10428194.2020.1713321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fotiou D, Gavriatopoulou M, Ntanasis-stathopoulos I, Migkou M, Dimopoulos MA, Terpos E. Updates on thrombotic events associated with multiple myeloma. Expert Review of Hematology 2019;12:355-65. [DOI: 10.1080/17474086.2019.1604214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Khorana AA, DeSancho MT, Liebman H, Rosovsky R, Connors JM, Zwicker J. Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist 2021;26:e2-7. [PMID: 33274815 DOI: 10.1002/onco.13569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Schoen MW, Carson KR, Luo S, Gage BF, Li A, Afzal A, Sanfilippo KM. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 2020;4:1203-10. [PMID: 33134785 DOI: 10.1002/rth2.12411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol 2022;13:757415. [DOI: 10.3389/fphar.2022.757415] [Reference Citation Analysis]
8 Leclerc V, Karlin L, Herledan C, Marchal L, Baudouin A, Gouraud A, Caffin AG, Larbre V, Lazareth A, Bachy E, Salles G, Ghesquières H, Rioufol C, Ranchon F. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. J Cancer Res Clin Oncol 2021. [PMID: 34143239 DOI: 10.1007/s00432-021-03693-5] [Reference Citation Analysis]
9 Kahale LA, Matar CF, Tsolakian I, Hakoum MB, Yosuico VE, Terrenato I, Sperati F, Barba M, Hicks LK, Schünemann H, Akl EA. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database Syst Rev 2021;9:CD014739. [PMID: 34582035 DOI: 10.1002/14651858.CD014739] [Reference Citation Analysis]
10 Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer 2020;126:1640-50. [PMID: 31913498 DOI: 10.1002/cncr.32682] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F, Garcia AVM, Angelini DE, Mazzoni S, Faiman B, Valent J, Khouri J. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 2021;193:1213-9. [PMID: 33997961 DOI: 10.1111/bjh.17505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020;136:1091-104. [PMID: 32438407 DOI: 10.1182/blood.2020005125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
13 Chalayer E, Tardy-Poncet B, Montmartin A, Boussoualim K, Genthon A, Tardy B. Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients. Br J Haematol 2019;186:337-9. [PMID: 30793294 DOI: 10.1111/bjh.15815] [Reference Citation Analysis]
14 Jones JR, Pawlyn C, Jackson GH. Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert Opin Drug Saf 2021;:1-9. [PMID: 34184970 DOI: 10.1080/14740338.2021.1945578] [Reference Citation Analysis]
15 Berbari HE, Kumar SK. Initial Therapeutic Approaches to Patients with Multiple Myeloma. Adv Ther 2021;38:3694-711. [PMID: 34145483 DOI: 10.1007/s12325-021-01824-5] [Reference Citation Analysis]
16 Bauersachs R, Khorana AA, Lee AYY, Soff G. Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. Res Pract Thromb Haemost 2020;4:532-49. [PMID: 32548552 DOI: 10.1002/rth2.12327] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fotiou D, Gavriatopoulou M, Terpos E. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel) 2020;12:E191. [PMID: 31940972 DOI: 10.3390/cancers12010191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
18 Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 2019;94:635-40. [PMID: 30859608 DOI: 10.1002/ajh.25459] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
19 Walsh M, Kwaan H, McCauley R, Marsee M, Speybroeck J, Thomas S, Hatch J, Vande Lune S, Grisoli A, Wadsworth S, Shariff F, Aversa JG, Shariff F, Zackariya N, Khan R, Agostini V, Campello E, Simioni P, Scărlătescu E, Hartmann J. Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility. Transfusion 2020;60 Suppl 6:S86-S100. [PMID: 33089937 DOI: 10.1111/trf.16102] [Reference Citation Analysis]
20 Fontes Oliveira M, Naaktgeboren WR, Hua A, Ghosh AK, Oakervee H, Hallam S, Manisty C. Optimising cardiovascular care of patients with multiple myeloma. Heart 2021:heartjnl-2020-318748. [PMID: 33820757 DOI: 10.1136/heartjnl-2020-318748] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]